Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMURF1 | Q9HCE7 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17256533 | 0.91 | SMURF1 (1.00) | SMURF1 | |
| SCHEMBL17256515 | 0.91 | SMURF1 (1.00) | SMURF1 | |
| SCHEMBL18393161 | 0.88 | SMURF1 (1.00) | SMURF1 | |
| SCHEMBL17256591 | 0.88 | SMURF1 (1.00) | SMURF1 | |
| SCHEMBL18393180 | 0.82 | SMURF1 (0.79) | SMURF1 | |
| SCHEMBL17256590 | 0.81 | SMURF1 (1.00) | SMURF1 | |
| SCHEMBL20706193 | 0.80 | SMURF1 (0.73) | SMURF1 | |
| SCHEMBL22377292 | 0.80 | SMURF1 (0.73) | SMURF1 | |
| SCHEMBL17256443 | 0.80 | SMURF1 (0.76) | SMURF1 | |
| SCHEMBL17266015 | 0.80 | SMURF1 (0.76) | SMURF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | claimed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | claimed |
| EP-3143018-B1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | claimed |
| US-20210052554-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2021-02-25 | — | — | US | claimed |
| US-20200268718-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | claimed |
| US-10195181-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | claimed |
| EP-3143018-A1 | CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2017-03-22 | — | — | EP | claimed |
| US-9403810-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | claimed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | claimed |
| WO-2015175796-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | WO | claimed |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11672782-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-9403810-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| WO-2015175796-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052554-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | SMURF1 4673/4885 |
| US-20230301970-A1 | CARBOXAMIDE DERIVATIVES | SIRT1, ADCY5, ASIC1 | SMURF1 4612/4885 |
| US-20150329529-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | SMURF1 4673/4885 |
| US-11672782-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | SMURF1 4673/4885 |
| US-20200268718-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | SMURF1 4673/4885 |
| US-10195181-B2 | Carboxamide derivatives | SIRT5, SIRT7, ADCY5 | SMURF1 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.